Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, generates frequent news across human health, animal health and corporate finance. As a research-intensive biopharmaceutical company with more than a century of history developing medicines and vaccines, Merck regularly announces clinical trial milestones, regulatory decisions, business development transactions and capital markets activity.
Recent news highlights include oncology updates from Merck’s extensive KEYTRUDA program, such as positive Phase 3 data in muscle-invasive bladder cancer and new trials in non-small cell lung cancer using combinations like calderasib (MK-1084) with KEYTRUDA QLEX. The company also reports on progress in other therapeutic areas, including pulmonary arterial hypertension with WINREVAIR, Alzheimer’s disease candidates MK-2214 and MK-1167, and cardiovascular research with the oral PCSK9 inhibitor candidate enlicitide.
Investors following MRK news will also see announcements related to Merck Animal Health, such as the conditional U.S. FDA approval of EXZOLT CATTLE-CA1 for the prevention and treatment of New World screwworm larvae and the treatment and control of cattle fever tick, as well as updates on acquisitions like the planned merger with Cidara Therapeutics to add the influenza candidate CD388 to Merck’s respiratory portfolio.
Corporate and financial communications include quarterly earnings calls, participation in major healthcare conferences and disclosures about note offerings under the company’s shelf registration statement. This news page aggregates these developments so readers can review clinical, regulatory, strategic and financial updates related to Merck & Co., Inc. and its MRK stock in one place.
Merck (NYSE: MRK) announced initiation of MALBEC, a pivotal Phase 2b/3 trial of MK-8748 (Tiespectus) for neovascular age-related macular degeneration (NVAMD) on April 2, 2026. The program follows Phase 1/2a RIOJA results and includes a second NVAMD study scheduled to begin later in 2026 (NCT07496567).
MK-8748 is a bispecific antibody that agonizes Tie2 and inhibits VEGF to target vascular leakage; Merck also advances MK-3000 in registrational Phase 2b/3 studies for diabetic macular edema.
Merck (NYSE: MRK) announced European Commission approval of KEYTRUDA (pembrolizumab) plus paclitaxel ± bevacizumab for adults with PD-L1 (CPS ≥1) platinum-resistant recurrent ovarian carcinoma after one or two prior systemic regimens.
The approval, based on Phase 3 KEYNOTE-B96, showed improved PFS (HR=0.72) and OS (HR=0.76) and covers all 27 EU member states plus Iceland, Liechtenstein and Norway; national reimbursement will determine local availability.
Merck (NYSE: MRK) will hold a first-quarter 2026 sales and earnings conference call at 9:00 a.m. ET on Thursday, April 30 for institutional investors and analysts. A live audio webcast will be available to the public.
A replay, the sales and earnings news release, supplemental financial disclosures and presentation slides will be posted at www.merck.com. Participants may join by dialing (800) 369-3351 (U.S./Canada) or (517) 308-9448 with access code 9818590.
Merck (NYSE: MRK) announced Phase 3 CORALreef AddOn results showing investigational oral PCSK9 inhibitor enlicitide decanoate reduced LDL-C by 64.6% at eight weeks versus baseline when added to statins and delivered significantly greater LDL-C reductions versus bempedoic acid, ezetimibe, and their combination.
Enlicitide improved goal attainment and key secondary lipids (ApoB, non‑HDL‑C, Lp(a)) with a safety profile consistent with prior CORALreef trials; FDA assigned a Commissioner’s National Priority Voucher in December 2025.
Merck (NYSE: MRK) reported positive Phase 2 CADENCE results for WINREVAIR (sotatercept-csrk) in adults with CpcPH-HFpEF, meeting the primary endpoint with a significant PVR reduction at week 24 (0.3 mg/kg: -1.02 WU, p=0.004; 0.7 mg/kg: -0.75 WU, p=0.024). Multiple hemodynamic, biomarker and clinical trends support advancing to a registrational Phase 3 program.
Merck (NYSE: MRK) agreed to acquire Terns Pharmaceuticals for $53.00 per share, valuing Terns at approximately $6.7 billion (about $5.7 billion net of acquired cash) with an expected close in Q2 2026.
The deal adds TERN-701, an oral allosteric BCR::ABL1 TKI in Phase 1/2 for certain CML patients with prior TKI exposure; TERN-701 has FDA Orphan Drug Designation (March 2024) and showed encouraging molecular responses by week 24. Merck expects a ~$5.8 billion charge (≈$2.35/share) in Q2 and full-year 2026 results; the transaction is subject to customary closing conditions and regulatory clearance.
Merck (NYSE: MRK) announced FDA approval (Mar 18, 2026) expanding the BRAVECTO® QUANTUM label to include Asian longhorned tick (H. longicornis) and Gulf Coast tick (A. maculatum) for 12 months after a single, veterinarian‑administered injection.
The product remains indicated for fleas and multiple other tick species (12 months for several species; 8 months for lone star tick) and is available exclusively through licensed veterinarians.
Merck (NYSE: MRK) will present new clinical and real-world data at the EUROGIN HPV Congress (March 18-21, 2026) in Vienna demonstrating long-term effectiveness of its HPV vaccines. Data show GARDASIL 9 effectiveness for at least 14 years after three doses and GARDASIL effectiveness up to 18 years after three doses against HPV16/18-related high-grade cervical disease.
The company will also present findings on certain HPV-related oropharyngeal cancers and trends in adult- and juvenile-onset recurrent respiratory papillomatosis from studies in the U.S., Denmark, Sweden, and the U.K.
Merck (NYSE: MRK) will present new cardio-pulmonary clinical data at ACC.26 (March 28-30, 2026) including two late-breaking presentations: positive Phase 3 CORALreef AddOn results for oral PCSK9 inhibitor enlicitide and positive Phase 2 CADENCE results for WINREVAIR™ (sotatercept-csrk) in CpcPH-HFpEF.
Presentations detail enlicitide efficacy/safety versus ezetimibe and bempedoic acid in statin-treated hypercholesterolemia and sotatercept outcomes in combined post-/pre-capillary pulmonary hypertension with HFpEF.
Merck (NYSE: MRK) reported Phase 3 LITESPARK-022 results: adjuvant KEYTRUDA + WELIREG reduced risk of recurrence or death by 28% (HR=0.72; p=0.0003) versus KEYTRUDA alone at median 28.4 months follow-up. Estimated 24-month DFS: 80.7% vs 73.7%. Grade ≥3 TEAEs occurred in 52.1% vs 30.2%. The FDA accepted supplemental applications with a PDUFA date of June 19, 2026.